Cell News and Research

RSS

Candidates turn health reform volume up as midterms near

A number of candidates for federal and state office are sounding off on how they view health reform.

18 Oct 2010

Vertex commences VX-770 and VX-809 combination Phase 2a clinical trial for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the safety and tolerability of VX-809 dosed alone for 14 days followed by dosing of VX-809 in combination with VX-770 for 7 days.

18 Oct 2010

Lake Health opens Northeast Ohio's first digital hospital

Lake Health made history last October when it opened TriPoint Medical Center, Northeast Ohio's first digital hospital. Now the health system is the first in the United States to deploy the latest generation of a digital wayfinding system featuring a virtual guide -- or avatar -- that helps patients and visitors navigate to their destinations quickly and easily.

18 Oct 2010

Fluticasone gets rid of eosinophils in the esophagus, but does not improve symptoms

A group of Mayo Clinic researchers conducted the first controlled trial of swallowed fluticasone nasal spray (also known as Flonase) on people with the allergic esophageal condition called eosinophilic esophagitis. Research showed that the aerosolized swallowed allergy drug helped treat the cause of the throat condition, but symptoms lingered. The researchers' findings were presented today at the Annual Scientific Meeting of the American College of Gastroenterology in San Antonio.

18 Oct 2010

FDA grants fast track designation for Aastrom's CLI cell therapy development program

Aastrom Biosciences, Inc., a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted fast track designation for the company's critical limb ischemia (CLI) cell therapy development program. Aastrom plans to initiate Phase 3 clinical testing of its treatment for CLI in early 2011.

18 Oct 2010

Atrium Medical receives Bio/Medical Council Business of the Year Award

The New Hampshire Bio/Medical Council held its 2nd Annual Awards Dinner on October 14, 2010 at the Wentworth-By-The-Sea Country Club in Rye, NH. During the evening, the Bio/Medical Council awarded Atrium Medical Corporation of Hudson, NH the NH Bio/Medical Council Business of the Year Award. In attendance to accept the award were Ted Karwoski, Chief Operating Officer and Steve Vail, Group VP of Global Marketing.

18 Oct 2010

Cryo-Cell board rejects unsolicited acquisition proposals

Cryo-Cell International, Inc., one of the world's largest and most established family cord blood banks and global stem cell innovator, today confirmed that it has recently received additional inquiries from third parties interested in acquiring the Company.

18 Oct 2010

NanoViricides' President delivers speech at ASNM Second Annual Conference

NanoViricides, Inc. announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).

18 Oct 2010

EC grants orphan drug designation to S*BIO's SB1518 for treatment of myelofibrosis

S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.

18 Oct 2010

OSU's Personalized Health Care National Conference focuses on P4 Medicine

Healthcare consumers took center stage at today's annual Ohio State University Medical Center Personalized Health Care National Conference. Speakers focused on ways that P4 Medicine – which is predictive, preventive, personalized and participatory – can revolutionize healthcare by engaging and empowering patients.

18 Oct 2010

ESHRE study shows advantages of CGH technique in IVF procedure

Two women taking part in the world's first controlled study of a comprehensive genetic screening test before IVF have given birth to healthy babies. The babies, twin girls born in Germany in June and a singleton boy born in Italy in September, are the first deliveries in a pilot study of comparative genomic hybridisation (CGH) by microarray, a new method of screening oocytes for IVF for a full range of chromosomal disorders.

18 Oct 2010

Metabolon announces publication of metabolic analysis of biochemical changes in CF primary lung epithelial cells

Metabolon, Inc., the leader in global metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells", in the Journal of Biological Chemistry.

18 Oct 2010

New discovery raises hopes for women with tamoxifen resistance

SCIENTISTS in London have found a potential new way of boosting the effectiveness of the anti-breast cancer drug, tamoxifen.

18 Oct 2010

Major advance in treatment of brain disorders with external genes

In the October 17 issue of Nature Methods, researchers at Thomas Jefferson University describe how they can transfer genes into brain neurons intravenously, using a viral gene delivery vehicle (vector) that causes no side effects.

18 Oct 2010

Celgene acquires Abraxis BioScience

Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.

18 Oct 2010

Researchers identify new paradigm for regulation of alternative splicing

How a T cell decides to make protein X, Y, or Z can have profound effects for fighting foreign invaders or staving off dire autoimmune reactions. Researchers at the University of Pennsylvania School of Medicine have identified the steps that control how different forms of an immune cell protein called CD45, which is critical for activating the immune system when faced with pathogens, are controlled in the arc of a body's immune response.

18 Oct 2010

Shrink reveals image of StemDisc450 biomedical research tool

Shrink Nanotechnologies, Inc. an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, revealed an image of its first product offering the StemDisc450, a high-yield, low cost, patent-pending cell culturing biomedical research tool.

18 Oct 2010

Genmab provides update on potential regulatory pathway for zalutumumab

Genmab A/S announced today an update on the potential regulatory pathway for zalutumumab following preliminary, non-binding discussions with a number of selected national European regulatory authorities and the FDA.

18 Oct 2010

Scientists find unexpected function of cell's protein-making machinery

When cells make the proteins that carry out virtually every function of life, it's vital that the right things happen at the right times, and maybe more importantly that wrong things are stopped from happening at the wrong times.

18 Oct 2010

UK Intellectual Property Office issues patent for entinostat

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced the UK Intellectual Property Office allowed application GB0907347.9 entitled N-(2-aminophenyl)-4-[N-(pyridine-3-YL)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B.

18 Oct 2010